Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors

Human Gene Therapy

Volumn 17, Issue 4, 2006, Pages 440-447

  Halbert, Christine L ^a   Miller, A Dusty ^a   McNamara, Sharon ^b   Emerson, Julia ^b   Gibson, Ronald L ^b   Ramsey, Bonnie ^b   Aitken, Moira L ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 6; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; RESPIRATORY EPITHELIUM; RISK ASSESSMENT; VIRAL GENE THERAPY; VIRUS CAPSID;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; INFANT; INFANT, NEWBORN; LUNG; MICE; SEROEPIDEMIOLOGIC STUDIES;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; ADENO-ASSOCIATED VIRUS - 5; ADENO-ASSOCIATED VIRUS 6; ANIMALIA; MIRIDAE; PARVOVIRUS; RODENTIA;

EID: 33645923713     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.440     Document Type: Article

References (32)

1. ALLEN, J.M., HALBERT, C.L., and MILLER, A.D. (2000). Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6. Mol. Ther. 1, 88-95.
2. AYERS, M.M., and JEFFERY, P.K. (1988). Proliferation and differentiation in mammalian airway epithelium. Eur. Respir. J. 1, 58-80.
3. BLACKLOW, N.R., HOGGAN, M.D., KAPIKIAN, A.Z., AUSTIN, J.B., and ROWE, W.P. (1968a). Epidemiology of adenovirus-associated virus infection in a nursery population. Am. J. Epidemiol. 88, 368-378.
4. BLACKLOW, N.R., HOGGAN, M.D., and ROWE, W.P. (1968b). Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst. 40, 319-327.
5. BLACKLOW, N.R., HOGGAN, M.D., SERENO, M.S., BRANDT, C.D., KIM, H.W., PARROTT, R.H., and CHANOCK, R.M. (1971). A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am. J. Epidemiol. 94, 359-366.
6. CHIRMULE, N., PROPERT, K., MAGOSIN, S., QIAN, Y., QIAN, R., and WILSON, J. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583.
7. DRUMM, M.L., POPE, H.A., CLIFF, W.H., ROMMENS, J.M., MARVIN, S.A., TSUI, L.C., COLLINS, F.S., FRIZZELL, R.A., and WILSON, J.M. (1990). Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62, 1227-1233.
8. DUAN, D., YUE, Y., YAN, Z., McCRAY, P.B., JR., and ENGELHARDT, J.F. (1998). Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum. Gene Ther. 9, 2761-2776.
9. ENGELHARDT, J.F., YANKASKAS, J.R., ERNST, S.A., YANG, Y., MARINO, C.R., BOUCHER, R.C., COHN, J.A., and WILSON, J.M. (1992). Submucosal glands are the predominant site of CPTR expression in the human bronchus. Nat. Genet. 2, 240-248.
10. HSCHER, A.C., BECK, S.E., SMITH, C.I., LAUBE, B.L., ASKIN, F.B., GUGGINO, S.E., ADAMS, R.J., FLOTTE, T.R., and GUGGINO, W.B. (2003). Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol. Ther. 8, 918-926.
11. FISHER, K.J., JOOSS, K., ALSTON, J., YANG, Y., HAECKER, S.E., HIGH, K., PATHAK, R., RAPER, S.E., and WILSON, J.M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3, 306-312.
12. GIBSON, R.L., BURNS, J.L., and RAMSEY, B.W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951.
13. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
14. HALBERT, C.L., and MILLER, A.D. (2004). AAV-mediated gene transfer to mouse lungs. Methods Mol. Biol. 246, 201-212.
15. HALBERT, C.L., STANDAERT, T.A., AITKEN, M.L., ALEXANDER, I.E., RUSSELL, D.W., and MILLER, A.D. (1997). Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration. J. Virol. 71, 5932-5941.
16. HALBERT, C.L., STANDAERT, T.A., WILSON, C.B., and MILLER, A.D. (1998). Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72, 9795-9805.
17. HALBERT, C.L., RUTLEDGE, E.A., ALLEN, J.M., RUSSELL, D.W., and MILLER, A.D. (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524-1532.
18. HALBERT, C.L., ALLEN, J.M., and MILLER, A.D. (2001). Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared with that of AAV2 vectors. J. Virol. 75, 6615-6624.
19. HERZOG, R.W., HAGSTROM, J.N., KUNG, S.H., TAI, S.J., WILSON, J.M., FISHER, K.J., and HIGH, K.A. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94, 5804-5809.
20. HERZOG, R.W., YANG, E.Y., COUTO, L.B., HAGSTROM, J.N., ELWELL, D., FIELDS, P.A., BURTON, M., BELLINGER, D.A., READ, M.S., BRINKHOUS, K.M., PODSAKOFF, G.M., NICHOLS, T.C., KURTZMAN, G.J., and HIGH, K.A. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56-63.
21. KESSLER, P.D., PODSAKOFF, G.M., CHEN, X., McQUISTON, S.A., COLOSI, P.C., MATELIS, L.A., KURTZMAN, G.J., and BYRNE, B.J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93, 14082-14087.
22. KOEBERL, D.D., ALEXANDER, I.E., HALBERT, C.L., RUSSELL, D.W., and MILLER, A.D. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 94, 1426-1431.
23. KOEBERL, D.D., BONHAM, L., HALBERT, C.L., ALLEN, J.M., BIRKEBAK, T., and MILLER, A.D. (1999). Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors. Hum. Gene Ther. 10, 2133-2140.
24. MANNING, W.C., ZHOU, S., BLAND, M.P., ESCOBEDO, J.A., and DWARKI, V. (1998). Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9, 477-485.
25. MOSS, R.B., RODMAN, D., SPENCER, L.T., AITKEN, M.L., ZEITLIN, P.L., WALTZ, D., MILLA, C., BRODY, A.S., CLANCY, J.P., RAMSEY, B., HAMBLETT, N., and HEALD, A.E. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 125, 509-521.
26. PARKS, W.P., BOUCHER, D.W., MELNICK, J.L., TABER, L.H., and YOW, M.D. (1970). Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect. Immun. 2, 716-722.
27. RUSSELL, D.W., MILLER, A.D., and ALEXANDER, I.E. (1994). Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. U.S.A. 91, 8915-8919.
28. SNYDER, R.O., MIAO, C.H., PATIJN, O.A., SPRATT, S.K., DANOS, O., NAGY, D., GOWN, A.M., WINTHER, B., MEUSE, L., COHEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276.
29. SUMMERFORD, C., and SAMULSKI, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
30. XIAO, W., CHIRMULE, N., BERTA, S.C., McCULLOUGH, B., GAO, G., and WILSON, J.M. (1999). Gene therapy vectors based on adeno-associated virus type I. J. Virol. 73, 3994-4003.
31. YANKASKAS, R.J., SUCHINDRAN, H., SARKODI, B., NETTESHEIM, P., and RANDELL, S. (1993). Cystic fibrosis transmembrane conductance regulator (CPTR) protein is selectively expressed in ciliated airway epithelial cells. Am. Rev. Respir. Dis. 147, A26.
32. ZABNER, J., SEILER, M., WALTERS, R., KOTIN, R.M., FULGERAS, W., DAVIDSON, B.L., and CHIORINI, J.A. (2000). Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74, 3852-3858.